• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与非微剂量使用者相比,使用迷幻剂微剂量的成年人报告称,他们的健康相关动机和焦虑、抑郁水平较低。

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.

机构信息

Department of Psychology, University of British Columbia, Kelowna, BC, Canada.

Department of Family Medicine, University of British Columbia, Vancouver, BC, Canada.

出版信息

Sci Rep. 2021 Nov 18;11(1):22479. doi: 10.1038/s41598-021-01811-4.

DOI:10.1038/s41598-021-01811-4
PMID:34795334
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8602275/
Abstract

The use of psychedelic substances at sub-sensorium 'microdoses', has gained popular academic interest for reported positive effects on wellness and cognition. The present study describes microdosing practices, motivations and mental health among a sample of self-selected microdosers (n = 4050) and non-microdosers (n = 4653) via a mobile application. Psilocybin was the most commonly used microdose substances in our sample (85%) and we identified diverse microdose practices with regard to dosage, frequency, and the practice of stacking which involves combining psilocybin with non-psychedelic substances such as Lion's Mane mushrooms, chocolate, and niacin. Microdosers were generally similar to non-microdosing controls with regard to demographics, but were more likely to report a history of mental health concerns. Among individuals reporting mental health concerns, microdosers exhibited lower levels of depression, anxiety, and stress across gender. Health and wellness-related motives were the most prominent motives across microdosers in general, and were more prominent among females and among individuals who reported mental health concerns. Our results indicate health and wellness motives and perceived mental health benefits among microdosers, and highlight the need for further research into the mental health consequences of microdosing including studies with rigorous longitudinal designs.

摘要

使用致幻物质进行亚感知“微剂量”,已引起学术界对其在健康和认知方面的积极影响的广泛关注。本研究通过移动应用程序,对自我选择的微剂量使用者(n=4050)和非微剂量使用者(n=4653)进行了微剂量使用实践、动机和心理健康的描述。在我们的样本中,最常使用的微剂量物质是裸盖菇素(85%),我们发现了各种不同的微剂量实践,包括剂量、频率以及叠加实践,叠加实践涉及将裸盖菇素与非致幻物质如狮鬃菇、巧克力和烟酸结合使用。微剂量使用者在人口统计学方面与非微剂量对照组大致相似,但更有可能报告存在心理健康问题。在报告存在心理健康问题的个体中,微剂量使用者在性别之间表现出更低水平的抑郁、焦虑和压力。一般来说,健康和福利相关的动机是微剂量使用者最突出的动机,而且在女性和报告存在心理健康问题的个体中更为突出。我们的结果表明,微剂量使用者存在健康和福利动机以及对心理健康益处的认知,并强调需要进一步研究微剂量对心理健康的影响,包括采用严格的纵向设计的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a90c/8602275/64a6411a2f98/41598_2021_1811_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a90c/8602275/9a1c818c9d30/41598_2021_1811_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a90c/8602275/64a6411a2f98/41598_2021_1811_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a90c/8602275/9a1c818c9d30/41598_2021_1811_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a90c/8602275/64a6411a2f98/41598_2021_1811_Fig2_HTML.jpg

相似文献

1
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.与非微剂量使用者相比,使用迷幻剂微剂量的成年人报告称,他们的健康相关动机和焦虑、抑郁水平较低。
Sci Rep. 2021 Nov 18;11(1):22479. doi: 10.1038/s41598-021-01811-4.
2
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.微剂量使用迷幻药:人口统计学、使用方法和精神共病。
J Psychopharmacol. 2020 Jun;34(6):612-622. doi: 10.1177/0269881120908004. Epub 2020 Feb 28.
3
Microdosing psychedelics: Motivations, subjective effects and harm reduction.微剂量使用迷幻剂:动机、主观效应和减少危害。
Int J Drug Policy. 2020 Jan;75:102600. doi: 10.1016/j.drugpo.2019.11.008. Epub 2019 Nov 25.
4
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.微剂量使用迷幻剂:微剂量使用者的个性、心理健康和创造力差异。
Psychopharmacology (Berl). 2019 Feb;236(2):731-740. doi: 10.1007/s00213-018-5106-2. Epub 2019 Jan 2.
5
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.迷幻蘑菇微剂量组在一个月时的情绪和心理健康方面表现出比非微剂量对照组更大的改善。
Sci Rep. 2022 Jun 30;12(1):11091. doi: 10.1038/s41598-022-14512-3.
6
Psychedelic microdosing benefits and challenges: an empirical codebook.迷幻药微剂量的好处和挑战:一个经验代码本。
Harm Reduct J. 2019 Jul 10;16(1):43. doi: 10.1186/s12954-019-0308-4.
7
Self-blinding citizen science to explore psychedelic microdosing.自我蒙蔽的公民科学探索迷幻微剂量。
Elife. 2021 Mar 2;10:e62878. doi: 10.7554/eLife.62878.
8
Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.微剂量使用迷幻药物:主观收益与挑战、物质检测行为,以及意图的相关性。
J Psychopharmacol. 2022 Jan;36(1):85-96. doi: 10.1177/0269881120953994. Epub 2020 Oct 8.
9
Psychedelic Microdosing: A Subreddit Analysis.迷幻微剂量:Reddit 分析。
J Psychoactive Drugs. 2020 Apr-Jun;52(2):101-112. doi: 10.1080/02791072.2019.1683260. Epub 2019 Oct 24.
10
Motives and Side-Effects of Microdosing With Psychedelics Among Users.使用迷幻剂进行微量给药的动机和副作用:使用者的观点
Int J Neuropsychopharmacol. 2019 Jul 1;22(7):426-434. doi: 10.1093/ijnp/pyz029.

引用本文的文献

1
Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.饮食失调或进食紊乱个体使用迷幻剂的情况:国际MED-FED调查结果
J Eat Disord. 2025 Jul 24;13(1):152. doi: 10.1186/s40337-025-01328-5.
2
Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?肠-脑轴能否为裸盖菇素在减轻压力方面的治疗价值提供见解?
Neurobiol Stress. 2025 May 19;36:100732. doi: 10.1016/j.ynstr.2025.100732. eCollection 2025 May.
3
A landscape analysis of psychedelic retreat organizations advertising online.

本文引用的文献

1
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review.微量服用迷幻药物时安慰剂效应的潜在安全性、益处及影响:一项系统综述
Neurosci Biobehav Rev. 2020 Dec;119:194-203. doi: 10.1016/j.neubiorev.2020.09.035. Epub 2020 Oct 5.
2
Psychedelics as a Treatment for Alzheimer's Disease Dementia.迷幻剂作为阿尔茨海默病性痴呆的一种治疗方法。
Front Synaptic Neurosci. 2020 Aug 21;12:34. doi: 10.3389/fnsyn.2020.00034. eCollection 2020.
3
Powerful substances in tiny amounts: An interview study of psychedelic microdosing.
对在线宣传的迷幻静修组织的景观分析。
PLoS One. 2025 May 2;20(5):e0321648. doi: 10.1371/journal.pone.0321648. eCollection 2025.
4
Exploring Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps.探索菌株:栽培技术、精神活性化合物、遗传学及研究空白
J Fungi (Basel). 2025 Jan 28;11(2):99. doi: 10.3390/jof11020099.
5
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.蘑菇、微剂量服用与精神疾病:裸盖菇素对神经递质、神经炎症和神经可塑性的影响。
Neuropsychiatr Dis Treat. 2025 Jan 29;21:141-155. doi: 10.2147/NDT.S500337. eCollection 2025.
6
Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery.探索运动员使用迷幻剂的情况及其对裸盖菇素辅助治疗脑震荡恢复的态度。
Ther Adv Psychopharmacol. 2024 Aug 7;14:20451253241264812. doi: 10.1177/20451253241264812. eCollection 2024.
7
Psilocybin for the treatment of Alzheimer's disease.用于治疗阿尔茨海默病的裸盖菇素
Front Neurosci. 2024 Jul 10;18:1420601. doi: 10.3389/fnins.2024.1420601. eCollection 2024.
8
Does LSD confer lasting psychological resilience? an investigation of naturalistic users experiencing job loss.LSD 是否能带来持久的心理适应力?对经历失业的自然使用者的调查。
PLoS One. 2024 Jun 20;19(6):e0304991. doi: 10.1371/journal.pone.0304991. eCollection 2024.
9
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.微剂量是安慰剂吗?低剂量 LSD 和裸盖菇素研究的快速综述。
J Psychopharmacol. 2024 Aug;38(8):701-711. doi: 10.1177/02698811241254831. Epub 2024 Jun 14.
10
Unlocking the self: Can microdosing psychedelics make one feel more authentic?释放自我:微剂量使用迷幻药能让人感觉更真实吗?
Nordisk Alkohol Nark. 2024 Apr;41(2):142-155. doi: 10.1177/14550725231175353. Epub 2023 May 24.
微量的强效物质:一项关于迷幻剂微剂量服用的访谈研究
Nordisk Alkohol Nark. 2018 Feb;35(1):39-51. doi: 10.1177/1455072517753339. Epub 2018 Feb 15.
4
Chemical Composition of Traditional and Analog Ayahuasca.传统与模拟“阿育吠陀”的化学成分。
J Psychoactive Drugs. 2021 Jan-Mar;53(1):65-75. doi: 10.1080/02791072.2020.1815911. Epub 2020 Sep 8.
5
Targeting the 5-HT system: Potential side effects.针对 5-HT 系统:潜在的副作用。
Neuropharmacology. 2020 Nov 15;179:108233. doi: 10.1016/j.neuropharm.2020.108233. Epub 2020 Aug 14.
6
The Current Status of Psychedelics in Psychiatry.精神药物在精神病学中的现状
JAMA Psychiatry. 2021 Feb 1;78(2):121-122. doi: 10.1001/jamapsychiatry.2020.2171.
7
Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.微剂量使用迷幻药:人口统计学、使用方法和精神共病。
J Psychopharmacol. 2020 Jun;34(6):612-622. doi: 10.1177/0269881120908004. Epub 2020 Feb 28.
8
Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.迷幻药微剂量自我管理治疗精神和物质使用障碍的感知结果。
Psychopharmacology (Berl). 2020 May;237(5):1521-1532. doi: 10.1007/s00213-020-05477-0. Epub 2020 Feb 11.
9
Psychedelic Microdosing: Prevalence and Subjective Effects.迷幻微剂量:流行程度和主观效应。
J Psychoactive Drugs. 2020 Apr-Jun;52(2):113-122. doi: 10.1080/02791072.2020.1718250. Epub 2020 Jan 23.
10
Therapeutic Potential of for Depressive Disorder.用于治疗抑郁症的潜力。
Int J Mol Sci. 2019 Dec 25;21(1):163. doi: 10.3390/ijms21010163.